Prosion

PROSION Therapeutics is a private, pre-revenue biotech company developing novel oncology therapeutics. Its core strategy involves utilizing a cutting-edge technology platform to generate antibodies against challenging, disease-relevant targets considered inaccessible to conventional drug modalities. With over two decades of operation, the company is positioned to advance its pipeline from discovery into clinical development, aiming to deliver new treatment options for cancer patients. Its success hinges on validating its platform and translating its research into clinically effective drugs.

Proprietary antibody discovery and engineering platform focused on generating therapeutics against traditionally undruggable targets, likely involving advanced display technologies and protein engineering.

PROSION competes in the crowded field of oncology-focused biotechs and platform companies, including those specializing in protein degradation, allosteric inhibition, and other modalities targeting undruggable proteins. Its success depends on demonstrating superior or unique capabilities in antibody generation against specific target classes compared to established players like AbCellera, Genmab, or large pharma internal efforts.